$4.85 billion settlement reached in Vioxx lawsuits
Company officials estimated the deal, if accepted, would end 45,000 to 50,000 personal injury lawsuits involving U.S. Vioxx users who suffered a heart attack or ischemic stroke, the type in which blood flow to the brain is blocked.
“Without this settlement, the litigation might very well stretch on for years,” Merck executive vice president Kenneth Frazier said during a conference call.
He called the agreement “responsible and reasonable” and allows Merck to better quantify its liability, once estimated as high as $50 billion. Negotiating teams met more than 50 times in eight states and spoke hundreds of times by telephone over many months to hammer out the deal, according to attorneys.
“I’m very happy with it,” said Chris Seeger, one of the six plaintiff lawyers who helped negotiate the settlement. “It’s a tremendous way to resolve this litigation.”
Merck pulled Vioxx from the market Sept. 30, 2004 after its researchers determined the blockbuster arthritis treatment, then pulling in about $2.5 billion a year, doubled risk of heart attacks and strokes.
To qualify for a settlement, plaintiffs must have filed claims by Thursday and meet several criteria, including medical proof that they suffered a heart attack or stroke, that they received at least 30 Vioxx pills and that they received enough pills to support a presumption that they were ingested within two weeks before injury.
That is a big concession by Merck, which has long claimed that Vioxx caused harm only after 18 months of use. Those claims were dismissed by independent scientists and plaintiffs lawyers.
Merck stressed the agreement is not a class action settlement and that it is not admitting fault.
Company executives and attorneys said as recently as last month that every case would be fought individually. On Friday, they said several factors made this “the right time” for the deal, including the expiration of the statute of limitations in 42 states.
Analyst Steve Brozak of WBB Securities called Merck’s handling of the litigation “a Harvard casebook study of how to deal with a problematic product.”
The deal becomes binding only if 85 percent of the plaintiffs in key categories agree to the deal: all pending heart attack and ischmic stroke cases, all cases involving deaths and all cases alleging more than 12 months of Vioxx use.
